BioNTech's exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3
Source: SeekingAlpha
2025-11-26 07:49:45 ET
More on BioNTech, CureVac BV
- BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript
- BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold
- BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript
- RFK Jr. ordered CDC change on vaccine link to autism claims
- Pfizer is said to divest remaining stake in BioNTech
Read the full article on Seeking Alpha
For further details see:
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3
CureVac N.V.
NASDAQ: CVAC
CVAC Trading
-14.23% G/L:
$4.64 Last:
558,418 Volume:
$4.57 Open:
CVAC Latest News
November 24, 2025 07:30:00 am
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
CVAC Stock Data
$1,045,416,278
124,238,526
N/A
39
N/A
Biotechnology & Life Sciences
Healthcare
DE
Tübingen
